SCA1—Phosphorylation,a regulator of Ataxin-1 function and pathogenesis |
| |
Authors: | Harry T. Orr |
| |
Affiliation: | Institute for Translational Neuroscience, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA |
| |
Abstract: | Spinocerebellar ataxia type 1 (SCA1) is one an intriguing set of nine neurodegenerative diseases caused by the expansion of a unstable trinucleotide CAG repeat where the repeat is located within the coding of the affected gene, i.e. the polyglutamine (polyQ) diseases. A gain-of-function mechanism for toxicity in SCA1, like the other polyQ diseases, is thought to have a major role in pathogenesis. Yet, the specific nature of this gain-of-function is a matter of considerable discussion. An issue concerns whether toxicity stems from the native or normal function of the affected protein versus a novel function induced by polyQ expansion. For SCA1 considerable evidence is accumulating that pathology is mediated by a polyQ-induced exaggeration of a native function of the host protein Ataxin-1 (ATXN1) and that phosphorylation of S776 regulates its interaction with other cellular protein and thereby function. In addition, this posttranslational modification modulates toxicity of ATXN1 with an expanded polyglutamine. |
| |
Keywords: | Akt, AKR mouse thymoma kinase ATXN1, vascular endothelial growth factor human Ataxin-1 dox, doxycycine NLS, nuclear localization sequence PKA, cyclic AMP-dependent protein kinase polyQ, polyglutamine RBM17, RNA binding motif protein 17 SCA1, Spinocerebellar ataxia type 1 Tta, tetracycline-transactivator TRE, tetracycline response element VEGF, vascular endothelial growth factor |
本文献已被 ScienceDirect 等数据库收录! |
|